An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate how efficiently the study medication imlifidase
reduces the amount of donor specific antibodies (DSA) in comparison with plasma exchange (PE)
therapy, in patients who have an active or chronic active antibody mediated rejection (AMR)
after recently been kidney transplanted. The purpose is also to investigate and compare
safety for these two treatments.
20 patients will be treated with imlifidase and 10 with PE.